Literature DB >> 33222915

Intracranial hemorrhage in critically ill patients hospitalized for COVID-19.

Islam Fayed1, Gnel Pivazyan1, Anthony G Conte1, Jason Chang2, Jeffrey C Mai3.   

Abstract

In this study, we report three cases of spontaneous intracranial hemorrhage in patients who were initially hospitalized at our tertiary care center in Washington, DC with symptoms of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in all three patients, who were critically ill, requiring intubation and ventilatory support. During their protracted hospitalizations, subsequent imaging disclosed intracranial hemorrhages, including intracerebral and subarachnoid hemorrhages, in the context of anticoagulation and coagulopathy. We believe this is related to the tropism of SARS-CoV-2 to the endothelial lining of the cerebral vasculature via their angiotensin-converting enzyme (ACE) II receptors. Given our findings, we advocate heightened vigilance for intracerebral hemorrhage events, and scanning when practicable, in COVID-19 patients which have prolonged ventilatory support and depressed neurologic examinations.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  COVID-19; Coagulopathy; Endothelial injury; Intracerebral hemorrhage; Subarachnoid hemorrhage

Mesh:

Year:  2020        PMID: 33222915      PMCID: PMC7434499          DOI: 10.1016/j.jocn.2020.08.026

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


We report three cases of spontaneous intracranial hemorrhage in patients who were initially hospitalized at our tertiary care center in Washington, DC with symptoms of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in all three patients, who were critically ill, requiring intubation and ventilatory support. During their protracted hospitalizations, subsequent imaging disclosed intracranial hemorrhages, including intracerebral and subarachnoid hemorrhages, in the context of anticoagulation and coagulopathy. Our first patient was a 57-year-old woman with past medical history of hypertension, obesity, sleep apnea, and asthma who presented to our emergency department (ED) with shortness of breath and fever. After testing positive for SARS-CoV-2, she was initially admitted to the floor and subsequently escalated to the intensive care unit (ICU) and intubated for hypoxic respiratory failure. She developed acute renal insufficiency, requiring continuous veno-venous hemofiltration under coverage of a heparin drip. Following two weeks of mechanical ventilation, a computed tomography (CT) scan of the head was performed given persistent encephalopathy, revealing a subacute lobar right frontal intracerebral hemorrhage (ICH) (Fig. 1 A). No coagulation or platelet dyscrasias were uncovered. Repeat CT imaging was stable, and following negative PCR testing for SARS-CoV-2, she was able to undergo contrasted magnetic resonance imaging (MRI), which did not disclosed an underlying pathology for the original ICH and revealed interval development of ICH in the left frontal lobe, despite being off heparization at that time (Fig. 1B and C). Interestingly, it also revealed significant inflammation of the sphenoid sinus – a putative mechanism for neuro-invasion by the virus (Fig. 1D). The patient was subsequently discharged to an acute rehabilitation facility one week later.
Fig. 1

A: Axial computed tomography (CT) of the head demonstrating a 3.5 × 3.4 × 3.2 cm acute intraparenchymal hematoma with inferior frontal midline shift. B,C: Axial magnetic resonance imaging (MRI) gradient echo (GRE) sequence demonstrating stable 3.2 cm right frontal intraparenchymal hematoma (B) with additional 0.6 cm left frontal intraparenchymal hematoma (C). D: Sagittal post-contrast T1 MRI with evidence of inflammation in the sphenoid sinus, a possible conduit for neuro-invasion by the virus. E, F: Axial (E) and coronal (F) non-contrast CT head demonstrating massive subarachnoid hemorrhage distributed throughout the basal cisterns with effacement of normal sulcal-gyri pattern. G,H: Axial (G) and sagittal (H) non-contrast CT head demonstrating a 2.2 × 2.2 cm intraparenchymal hemorrhage with surrounding hypodensity, suspicious for hemorrhagic transformation of a right-sided posterior cerebral artery (PCA) infarction.

A: Axial computed tomography (CT) of the head demonstrating a 3.5 × 3.4 × 3.2 cm acute intraparenchymal hematoma with inferior frontal midline shift. B,C: Axial magnetic resonance imaging (MRI) gradient echo (GRE) sequence demonstrating stable 3.2 cm right frontal intraparenchymal hematoma (B) with additional 0.6 cm left frontal intraparenchymal hematoma (C). D: Sagittal post-contrast T1 MRI with evidence of inflammation in the sphenoid sinus, a possible conduit for neuro-invasion by the virus. E, F: Axial (E) and coronal (F) non-contrast CT head demonstrating massive subarachnoid hemorrhage distributed throughout the basal cisterns with effacement of normal sulcal-gyri pattern. G,H: Axial (G) and sagittal (H) non-contrast CT head demonstrating a 2.2 × 2.2 cm intraparenchymal hemorrhage with surrounding hypodensity, suspicious for hemorrhagic transformation of a right-sided posterior cerebral artery (PCA) infarction. The second patient is a 54-year-old female with past medical history of hypertension, obesity, and bilateral mastectomy in 2016 for BRCA2 mutant breast cancer who presented to our ED with four days of myalgia and fever. After testing positive for SARS-CoV-2, she was discharged to home, but was admitted two days later with dyspnea and hypoxia necessitating mechanical ventilation. She continued to deteriorate, entering vasodilatory shock requiring vasopressors and epoprostenol treatment with prone positioning. She had a transient thrombocytopenia and was placed on a heparin drip for thromboembolic protection. At 24 h following cessation of heparin drip, at one week post-intubation, the patient developed dilated and non-reactive pupils on hourly neurologic checks and CT images of the head disclosed diffuse subarachnoid hemorrhage with intraventricular extension and sulcal effacement (Fig. 1E and F). She progressed to brain death and expired due to asystole four days later (Table 1 ).
Table 1

Clinical Characteristics of Three COVID+ Patients who Developed Intracranial Hemorrhages.

Case 1Case 2Case 3
Age – years575471
GenderFemaleFemaleMale
Medical HistoryObesitySleep ApneaAsthmaHypertensionBilateral Mastectomy (BRCA2 mutant breast cancer)HypertensionType II Diabetes MellitusChronic Kidney DiseaseB-Cell Lymphoma (In Remission)
Relevant MedicationsAspirin 81 mgAspirin 81 mgPlacebo vs SarilumabEpoprostenolDesmopressinN/A
Presenting COVID SymptomsShortness of BreathFeverBody AchesFeverHypoxiaShortness of BreathDizziness
Hospital Stay Prior to ICH – days20820
Duration of Intubation Prior to ICH – days18815
Prone Positioning+++
Other Critical Care NeedsVasopressorsContinuous Veno-Venous HemofiltrationVasopressorsVasopressors
Anticoagulation (Duration)Heparin drip (6 days)Heparin drip (30 h)N/A
Symptom Prompting Head ImagingPersistent EncephalopathyFixed and Dilated PupilsPersistent Encephalopathy
Type and location of ICHRight Frontal Lobar Intracerebral HemorrhageDiffuse Subarachnoid HemorrhageRight PCA distribution infarctwith hemorrhagic conversion
Imaging Studies PerformedCT and MRICT and Nuclear Medicine StudyCT
Laboratory Values – At Presentation/At Time of ICH/Minimum-Maximum
White Blood Cell Count – per mm310,700/24,800/8800–91,0008300/17,300/5200–18,20010,200/9300/5300–18,600
Platelet Count – per mm3200,000/181,000/159,00–506,000135,000/123,000/17,000–137,000207,000/354,000/64,000–360,000
Prothrombin Time – seconds13.2/13.9/13.2–15.713.0/14.5/13.0–14.813.5/20.3/13.2–20.3
Activated Partial-Thromboplastin Time – seconds33.2/20.8/20.8–40.925.1/48.2/25.1–48.2N/A/57.3/57.3–65.7
International Normalized Ratio1.0/1.1/1.0–1.21.0/1.1/1.0–1.21.0/1.7/1.0–1.7
Anti-Xa – IU/mLN/A/N/A/0.23–1.10N/A/0.26/0.97–1.10N/A
Fibrinogen – mg/dLN/A/638/382–1214630/308/308–788672/1276/672–1276
D-dimer – mcg/mL1.06/14.08/1.06–18.630.52/13.79/0.52–20.001.44/9.55/1.44–9.88
OutcomeAcute rehabilitationCerebral circulatory arrestconfirmed by nuclear medicine studyPalliative extubation

ICH: intracranial hemorrhage; CT: computed tomography; MRI: magnetic resonance imaging; PCA: posterior cerebral artery.

Clinical Characteristics of Three COVID+ Patients who Developed Intracranial Hemorrhages. ICH: intracranial hemorrhage; CT: computed tomography; MRI: magnetic resonance imaging; PCA: posterior cerebral artery. The third patient is a 71-year-old gentleman with past medical history of hypertension, type II diabetes, chronic kidney disease, and B-cell lymphoma in remission who presented to the ED with acute onset shortness of breath and dizziness. After testing positive for SARS-CoV-2, the patient was admitted, progressing from a 15-liter supplement oxygen requirement to intubation, prone positioning, and vasopressor support within 5 days of admission. At two weeks post-intubation, persistent encephalopathy promoted a surveillance head CT, which disclosed a right occipital ICH with surrounding edema suggestive of hemorrhagic conversion of an infarct (Fig. 1G and H). D-dimer and fibrinogen were elevated to 3.2mcg/mL (normal range 0–0.72 mcg/mL) and 1018 mg/dL (normal range 213–536 mg/dL), respectively, indicating a hypercoagulable state. While international normalized ratio (INR) and platelet counts were within normal range prior to the hemorrhage, they subsequently became profoundly hypercoagulable and thrombocytopenic afterwards, suspicious for disseminated intravascular coagulation (DIC). While the ICH remained stable on repeat imaging, the patient ultimately succumbed to multi-system organ failure one week later. These cases support the predisposition of COVID-19 patients to the development of intracranial hemorrhage during critical illness. The pathophysiology is unclear, but the tropism of SARS-CoV-2 to the endothelial lining of the cerebral vasculature via their angiotensin-converting enzyme (ACE) II receptors, remains a possibility [1], [2], and a recent pathology study The Lancet demonstrated the presence of virus particles within endothelial cells and an accumulation of inflammatory cells, leading to endothelial cell death [3]. Furthermore, a recent Italian review of animal studies suggests a higher neuro-invasive property of SARS-CoV-2 compared to other coronaviruses [4]. Zhou et al were able to detect SARS-CoV-2 RNA in human cerebrospinal fluid, and neurologic sequelae have been observed in an estimated 36% of COVID-19 patients [5], [6], [7]. Postmortem brain studies have also shown direct invasion of neurons and glial cells [8], [9]. Several studies have suggested a pro-thrombotic state in these patients, possibly related to antiphospholipid antibodies, which may lead to ischemic complications related to occlusion of the cerebral vasculature [10], [11], [12], [13], [14], [15]. Additionally, numerous reports of ICH in COVID-19 have begun to accumulate in the literature [16], [17], [18], [19], [20]. Collectively, these findings corroborate the possibility of direct cerebrovascular endothelial injury, vascular injury, and DIC leading to cerebral hemorrhagic events, exacerbated by concomitant anticoagulation therapy in two instances. The ability to identify and treat these patients is hindered by the strict isolation and precautions mandated by COVID-19 infection. Given our findings, we advocate heightened vigilance for intracerebral hemorrhage events, and scanning when practicable, in COVID-19 patients which have prolonged ventilatory support and depressed neurologic examinations.
  20 in total

1.  Cerebrovascular Disease in Patients with COVID-19: A Review of the Literature and Case Series.

Authors:  Sujan T Reddy; Tanu Garg; Chintan Shah; Fábio A Nascimento; Rajeel Imran; Peter Kan; Ritvij Bowry; Nicole Gonzales; Andrew Barreto; Abhay Kumar; John Volpi; Vivek Misra; David Chiu; Rajan Gadhia; Sean I Savitz
Journal:  Case Rep Neurol       Date:  2020-06-11

2.  Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study.

Authors:  Yanan Li; Man Li; Mengdie Wang; Yifan Zhou; Jiang Chang; Ying Xian; David Wang; Ling Mao; Huijuan Jin; Bo Hu
Journal:  Stroke Vasc Neurol       Date:  2020-07-02

3.  Letter: Hemorrhagic Conditions Affecting the Central Nervous System in COVID-19 Patients.

Authors:  Sergio García-García; Santiago Cepeda; Ignacio Arrese; Rosario Sarabia
Journal:  Neurosurgery       Date:  2020-09-01       Impact factor: 4.654

4.  COVID-19 and Cerebral Hemorrhage: Proposed Mechanisms.

Authors:  Mohamad Syafeeq Faeez Md Noh
Journal:  J Neuroradiol       Date:  2020-06-01       Impact factor: 3.447

5.  Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description.

Authors:  Francisco Hernández-Fernández; Hernán Sandoval Valencia; Rosa Angélica Barbella-Aponte; Rosa Collado-Jiménez; Óscar Ayo-Martín; Cristina Barrena; Juan David Molina-Nuevo; Jorge García-García; Elena Lozano-Setién; Cristian Alcahut-Rodriguez; Álvaro Martínez-Martín; Antonio Sánchez-López; Tomás Segura
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

6.  Endothelial cell infection and endotheliitis in COVID-19.

Authors:  Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch
Journal:  Lancet       Date:  2020-04-21       Impact factor: 79.321

Review 7.  The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review.

Authors:  Sheng-Ta Tsai; Ming-Kuei Lu; Shao San; Chon-Haw Tsai
Journal:  Front Neurol       Date:  2020-05-19       Impact factor: 4.003

8.  COVID-19 and intracerebral haemorrhage: causative or coincidental?

Authors:  A Sharifi-Razavi; N Karimi; N Rouhani
Journal:  New Microbes New Infect       Date:  2020-03-27

Review 9.  Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms.

Authors:  Zhiqiang Zhou; Huicong Kang; Shiyong Li; Xu Zhao
Journal:  J Neurol       Date:  2020-05-26       Impact factor: 4.849

10.  Explanation for COVID-19 infection neurological damage and reactivations.

Authors:  Kevin Roe
Journal:  Transbound Emerg Dis       Date:  2020-05-04       Impact factor: 4.521

View more
  12 in total

1.  Non-Aneurysmal Subarachnoid Hemorrhage in COVID-19: A Case Report and Review of Literature.

Authors:  Ritwik Ghosh; Dipayan Roy; Adrija Ray; Amrita Mandal; Shambaditya Das; Shyamal Kanti Pal; Julián Benito-León
Journal:  Med Res Arch       Date:  2022-01-30

2.  Age-Associated Neurological Complications of COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Brianne N Sullivan; Tracy Fischer
Journal:  Front Aging Neurosci       Date:  2021-08-02       Impact factor: 5.750

3.  Neuropathologic findings of patients with COVID-19: a systematic review.

Authors:  Azalea T Pajo; Adrian I Espiritu; Almira Doreen Abigail O Apor; Roland Dominic G Jamora
Journal:  Neurol Sci       Date:  2021-01-22       Impact factor: 3.830

Review 4.  The relationship between COVID-19 infection and intracranial hemorrhage: A systematic review.

Authors:  Samuel R Daly; Anthony V Nguyen; Yilu Zhang; Dongxia Feng; Jason H Huang
Journal:  Brain Hemorrhages       Date:  2021-11-11

5.  A case-based systematic review on the SARS-COVID-2-associated cerebrovascular diseases and the possible virus routes of entry.

Authors:  Ali Lashkari; Reza Ranjbar
Journal:  J Neurovirol       Date:  2021-09-21       Impact factor: 2.643

6.  Vertebral artery dissecting aneurysm rupture under severe COVID-19.

Authors:  Takenori Sato; Yoichi Miura; Ryuta Yasuda; Naoki Toma; Hidenori Suzuki
Journal:  Brain Hemorrhages       Date:  2022-08-12

7.  Clinical patterns of endothelial damage and thrombotic events in two patients with COVID-19: A case report.

Authors:  Minoosh Moghimi; Kasra Khodadadi; Mehdi Sarvandi
Journal:  Clin Case Rep       Date:  2021-07-06

Review 8.  Intracerebral hemorrhage in COVID-19: A narrative review.

Authors:  Nikolaos Panagiotis Margos; Andreas Stylianos Meintanopoulos; Dimitrios Filioglou; John Ellul
Journal:  J Clin Neurosci       Date:  2021-05-04       Impact factor: 2.116

Review 9.  Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: A critical systematic review.

Authors:  Giuseppe Cosentino; Massimiliano Todisco; Noy Hota; Giovanni Della Porta; Patrizia Morbini; Cristina Tassorelli; Antonio Pisani
Journal:  Eur J Neurol       Date:  2021-08-17       Impact factor: 6.288

10.  Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  Brain Hemorrhages       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.